Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2026-09-03 16:29:51 ET · period of report 2026-09-01 · accession 0001842190-26-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-09-03 16:29 | 2026-09-01+ | TARS | Lin Elizabeth Yeu | Chief Medical Off | S - Sale | $77.17 | -9,988 | 13.3K | -43% | -$770.8K |
| TI | 2026-09-03 16:29 | 2026-09-02 | TARS | Lin Elizabeth Yeu | Chief Medical Off | S - Sale | $80.00 | -1,590 | 4,770 | -25% | -$127.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-01 | S | D | 4,601 | $73.86 | 18,707 | D | — | — | (F1) The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026. |
| 2 | Common | Common Stock | 2026-09-02 | S | D | 5,387 | $80.00 | 13,320 | D | — | — | (F1) The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026. |
| 3 | Common | Common Stock | 2026-09-02 | S | D | 1,590 | $80.00 | 4,770 | I By Spouse's Roth IRA | — | — | (F2) The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026. |